

β -Adrenoceptors

Key References

- Bylund, D.B. et al. "Adrenoceptors." in: *The IUPHAR Compendium of Receptor Characterization and Classification, 2nd edition*, pp. 88-103, IUPHAR Media, London, UK (2000).
- Collins, S., Surwit, R.S. "The beta-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis." *Recent Prog. Horm. Res.* **56**, 309-328 (2001).
- Freestone, N.S. et al. " β_4 -Adrenoceptors are more effective than β_1 -adrenoceptors in mediating arrhythmic Ca^{++} transients in mouse ventricular myocytes." *Naunyn Schmiedebergs Arch. Pharmacol.* **360**, 445-456 (1999).
- Gauthier, C. et al. "Beta3-adrenoceptors in the cardiovascular system." *Trends Pharmacol. Sci.* **21**, 426-431 (2000).
- Hieble, J.P. "Drugs targeting adrenergic receptors: Does interaction with a specific subtype confer therapeutic advantage?" *Curr. Opin. Drug Disc. Dev.* **3** 370-382 (2000).
- Hieble, J.P. et al. "Alpha and beta-adrenoceptors: From the gene to the clinic. Part 1." *J. Med. Chem.* **38**, 3415-3444 (1995).
- Kaumann, A.J. et al. "(-)-CGP12177 causes cardiostimulation and binds to cardiac putative β_4 -adrenoceptors in both wild-type and β_3 -adrenoceptor knock-out mice." *Mol. Pharmacol.* **53**, 670-675 (1998).
- Ostrowski, J. et al. "Mutagenesis of the beta 2 adrenergic receptor: How structure elucidates function." *Annu. Rev. Pharmacol. Toxicol.* **32**, 167-183 (1992).
- Ruffolo, R.R., Jr. et al. "Alpha- and beta-adrenoceptors: From the gene to the clinic. Part 2." *J. Med. Chem.* **38**, 3681-3716 (1995).
- Sato, Y. et al. "Molecular characterization of pharmacological properties of T-0509 for β -adrenoceptors." *Eur. J. Pharmacol.* **315**, 363-367 (1996).
- Sennitt, M.V. et al. "The contribution of classical $\beta_{1/2}$ and atypical β -adrenoceptors to the stimulation of human white adipocyte lipolysis and right atrial appendage contraction by novel β_3 -adrenoceptor agonists of differing selectivities" *J. Pharmacol. Exp. Ther.* **285** 1084-1095 (1998).
- Weyer, C. et al. "Increase in insulin action and fat oxidation after treatment with CL-316,243, a highly selective β_3 -adrenoceptor agonist in humans." *Diabetes* **47**, 1555-1561 (1998).

Overview

β -Adrenoceptors are widely distributed, found at both central and peripheral sites, and are activated either via norepinephrine released from sympathetic terminals or via epinephrine released from the adrenal medulla. Important physiological consequences of β -adrenoceptor activation include stimulation of cardiac rate and force, relaxation of vascular, urogenital and bronchial smooth muscle, stimulation of renin secretion from the juxta-glomerular apparatus, stimulation of insulin and glucagon secretion from the endocrine pancreas, stimulation of glycogenolysis in liver and skeletal muscle and stimulation of lipolysis in the adipocyte. Prejunctional β -adrenoceptors are present on some central and peripheral nerve terminals, where their activation results in facilitation of stimulation-evoked neurotransmitter release. However, in contrast to the prejunctional α_2 -adrenoceptors, these prejunctional receptors do not appear to have major physiologic significance. Most β -adrenoceptor mediated actions involve stimulation of adenylyl cyclase via interaction of the agonist-receptor complex with G_s .

Three β -adrenoceptor proteins have been cloned, and the characteristics of these recombinant receptors correspond with those of the three well characterized β -adrenoceptors on native tissues, designated as β_1 , β_2 and β_3 . Species differences appear to be important for the β_3 -adrenoceptor, since several selective β_3 -adrenoceptor agonists can activate rodent, but not human β_3 -adrenoceptors. There is experimental evidence for the presence of an additional β -adrenoceptor, tentatively designated as the β_4 -adrenoceptor,

modulating cardiac contractility. However, it is possible that these data may be explained by multiple affinity states of the β_1 -adrenoceptor.

Many useful pharmacological tools are available for β -adrenoceptor characterization. These include agonists capable of selectively activating β_1 -, β_2 - or β_3 -adrenoceptors, as well as antagonists selective for each of the three subtypes. While it was initially thought that cardiac stimulation involved primarily the β_1 -adrenoceptor, it now appears that all of the receptor subtypes may be involved. Bronchodilation appears to be mediated primarily by the β_2 -adrenoceptor. The β_3 -adrenoceptor is responsible for lipolysis in white adipose tissue and thermogenesis in the brown adipose tissue found in rodents. Renin release appears to be mediated by the β_1 -adrenoceptor.

β_2 -Adrenoceptor agonists are commonly used as bronchodilators. Selective β_3 -adrenoceptor agonists are being developed for the treatment of type II diabetes and obesity. β -Adrenoceptor antagonists, either non subtype-selective or selective for the β_1 -adrenoceptor, are widely used as antihypertensives, although the mechanism for this action is still not clearly understood. Intra-ocular administration of nonselective β -adrenoceptor antagonists is a common treatment for glaucoma. Carvedilol, a molecule combining non-selective β -adrenoceptor blockade with α_1 -adrenoceptor blockade, has recently been shown to produce a dramatic reduction in the mortality/morbidity associated with congestive heart failure.

β-Adrenoceptors

CURRENTLY ACCEPTED NAME	β ₁ (B-143)	β ₂ (B-144)	β ₃
ALTERNATE NAME	—	—	atypical β
STRUCTURAL INFORMATION	477 aa (human)	413 aa (human)	408 aa (human)
SUBTYPE SELECTIVE AGONISTS	Norepinephrine (A 7257) Xamoterol Denopamine T-0509	Procaterol (P 9180) Salbutamol (S 8260 , S 5013) Fenoterol (F 1016)	BRL 37344 (B-169) CL 316243 (C 5976) SB-226552
SUBTYPE SELECTIVE ANTAGONISTS	CGP20712A (C-231) Betaxolol (B 5683) Atenolol (A 7655)	ICI-118,551 (I-127) Butoxamine (B 1385) α-Methylpropranolol	SR 58894 SR 59230A (S 8688)
RECEPTOR SELECTIVE AGONIST	Isoproterenol (I 5627)	Isoproterenol (I 5627)	Isoproterenol (I 5627)
RECEPTOR SELECTIVE ANTAGONISTS	Alprenolol (A 8676) Propranolol (P 0884 , P 8688) Pindolol (P 0778)	Alprenolol (A 8676) Propranolol (P 0884 , P 8688) Pindolol (P 0778)	Bupranolol Cyanopindolol (C-238)
SIGNAL TRANSDUCTION MECHANISMS	G _s (increase cAMP)	G _s (increase cAMP)	G _s (increase cAMP)
RADIOLIGAND OF CHOICE	[¹²⁵ I]-I-ICYP	[¹²⁵ I]-I-ICYP	[¹²⁵ I]-I-ICYP

ABBREVIATIONS

BRL 37344: (±)-(R*,R*)-(4-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy)acetic acid

CGP20712A: (±)-2-Hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl]phenoxy]propyl]-amino]ethoxy]-benzamide methanesulfonate

CL 316243: (R,R)-5-[2-[[2-(3-Chlorophenyl)-2-hydroxyethyl]-amino]-propyl]1,3-benzodioxole-2,2-dicarboxylate

ICI-118,551: (±)-1-[2,3-(Dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol

ICYP: Iodocyanopindolol

SB-226552: (S)-4-[2-[2-Hydroxy-3-(4-hydroxyphenoxy)propylamino]ethyl]phenoxyethylcyclohexylphosphinic acid

SR 58894: 3-(2-Allylphenoxy)-1-[(1S)-1,2,3,4-tetrahydronaphth-1-ylamino]-(2S)-2-propanol hydrochloride

SR 59230: 3-(2-Ethylphenoxy)-1-[(1S)-1,2,3,4-tetrahydronaphth-1-ylamino]-(2S)-2-propanol oxalate

T-0509: [(–)-(R)-1-(3,4-Dihydroxyphenyl)-2-[(3,4-dimethoxyphenethyl)-amino]ethanol